Du är här


Galapagos NV: Galapagos reports results with GLPG1205 in ulcerative colitis

* Phase 2a study confirms good pharmacokinetics, safety and tolerability
* In ulcerative colitis patients, primary endpoint for efficacy was not met

Mechelen, Belgium; 26 January 2016; 7.30 CET - Galapagos NV (Euronext&NASDAQ:
announced today that the ORIGIN Phase 2a study with GLPG1205 confirmed good
pharmacokinetics, safety and tolerability. The endpoints for efficacy of
GLPG1205 in patients with ulcerative colitis (UC), however, were not met.
Galapagos will discontinue clinical development in UC.

The ORIGIN study results showed that GLPG1205 did not statistically
significantly differentiate from placebo on (partial) Mayo scores. GLPG1205
was shown to be overall safe and well-tolerated by patients in the ORIGIN
study; exposure data were in line with the healthy volunteer data from the
previous Phase 1 clinical study. Further details about the ORIGIN study will
be published later during 2016.
Galapagos will evaluate whether GLPG1205 will be developed in alternative

About Galapagos

Galapagos(Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises two Phase 2, four Phase 1,
five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring this
JAK1-selective inhibitor for inflammatory indications to patients all over
the world. Galapagos is focused on the development and commercialization of
novel medicines that will improve people's lives. The Galapagos group,
including fee-for-service subsidiaryFidelta, has approximately 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information atwww.glpg.com.

Galapagos Contacts

Investors: Media:

Elizabeth Goodwin Evelyn Fox
VP IR&Corporate Communications Director Communications
Tel: +1 781 460 1784 Tel: +31 6 53
591 999
E-mail:ir@glpg.com E-mail:

Forward-Looking Statements

This release may contain forward-looking statements, including statements
regarding the potential future development of GLPG1205 in alternative
indications, the activity of GLPG1205 in alternative indications. Galapagos
cautions the reader that forward-looking statements are not guarantees of
future performance. Forward-looking statements involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even
if Galapagos' results, performance, financial condition and liquidity, and
the development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities and
regulatory approval requirements (including that data from Galapagos'
clinical research program with GLPG1205 may not support registration or
further development of GLPG1205 due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties (including the
performance by Gilead under the global license and collaboration agreement on
filgotinib), and estimating the commercial potential of our product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in the company's Securities and Exchange Commission
filing and reports, including in the company's prospectus filed with the
Securities and Exchange Commission on May 14, 2015 and subsequent filings and
reports filed by the company with the Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.